facebook twitter linkedin
news and events

This material was prepared by a third party towards Selvita S.A. with its registered office in Kraków (hereunder: “Selvita”). Within the scope which was not authorized by Selvita’s management board, the description of factual circumstances regarding the activities of Selvita, embodied in this material presents merely opinion of the third party, in particular with respect to presented opinions, predictions, appraisals and forecasts of the financial data and future activity of Selvita and its results.

Therefore, Selvita does not warrant consistency of this material with the actual and legal situation. Neither Selvita, members of its corporate bodies, employees nor its consultants shall bear any liability for validity of opinions, predictions, appraisals, forecasts and any other date embodied in this material as well as for consequences of actions of any reader made on a basis of this material, in particular for the investment decisions or any losses resulting from use of this material.

Readers of this material shall make its own assessment, whether opinions or forecasts embodied therein are credible and adequate, in particular taking into account their investment strategy and actual and legal situation. In particular they should consult it with their independent financial and investment advisors. None of the information presented in this material shall constitute investment, legal, accounting or tax advice or a statement that any investment strategy is accurate or adequate, considering the circumstances of the reader.

Furthermore date presented in this material shall not constitute an offer to sell or purchase any financial instruments nor an invite the make such offer. It shall not be also not deemed as a recommendation for investment in any financial instrument nor an advertisement of such instruments.



DISAGREE AGREE

News archive

  • Kraków, Poland - 22 April 2016 - Selvita will participate in the upcoming BioTrinity 2016 conference, which will take place on 25 - 27 April 2016, in London, UK.   BioTrinity is the Europe's leading investment and biopartnering conference, constituting the nexus of a booming life sciences innovation ecosystem and provides a unique platform...
  • Kraków, Poland - April 18, 2016 - Selvita (WSE:SLV), the largest drug discovery company in Central and Eastern Europe, has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for SEL24, the first compound to advance in clinical development from the company's internal discovery...
  • Krakow, 29 March 2016 – Selvita will participate in and present at the upcoming BIO-Europe Spring which is the springtime counterpart to EBD Group’s flagship conference, BIO-Europe, and continues the tradition of providing life science companies with high caliber partnering opportunities.   The upcoming edition of the BIO-Europe Spring...
  • Krakow, Poland, November 6, 2015 - Selvita, the largest drug discovery company in Central and Eastern Europe, will publish the most recent data from its oncology programs at the upcoming 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, which is taking place on 05 – 09 November 2015, in Boston, Massachusetts,...
  •   Krakow, 26 October 2015 - Selvita will participate and present at the upcoming Drug Discovery USA Congress, which will be held on 29 - 30 October 2015, in Boston, USA.   Dr Lars van der Veen, Director Alliance Manager at Merck, together with Dr Krzysztof Brzozka, Selvita's Chief Scientific Officer, will deliver a presentation...
  • Krakow, 23 October 2015 - Selvita will participate in the upcoming BIO-Europe 2015 conference. This year's edition of the event will take place on 02-04 November 2015, in Munich, Germany.   Selvita will hold a presentation during the event, presenting in the Cancer category. The presentation will take place on November 4, at 11:45 a.m., in...
  • Krakow, 20 October 2015 - Selvita is a proud sponsor of the upcoming Science: Polish Perspectives conference, which will take place on October 30-31, in Cambridge, United Kingdom.   Science: Polish Perspectives is a popular science conference directed at young researchers, PhD students and undergraduates of Polish origin, conducting their...
  • Krakow, Poland, 9 October 2015 - Selvita will participate in one of the greatest annual pharmaceutical events - CPhI Worldwide event, co-located with the ICSE | BioPh and InnoPack and P-MEC Europe for Pharmaceutical Machinery, Equipment and Technology, is an unrivalled networking and business event for the global pharma community. It brings...
  •   Krakow, Poland, 07 October 2015 - Selvita will participate in the upcoming edition of the BIO Latin America Conference. The conference will take place in Rio de Janeiro, in Brazil, from 14 - 16 October 2015.   Bio Latin is an initiative of the renowned Biotechnology Industry Organization, the organizer of the annual BIO Convention...
  •   Krakow, 21 September 2015 – Selvita will participate in the upcoming Biotech Outsourcing Strategies 2015 - Discovery/Early Development & Clinical Outsourcing Tracks, which will take place September 22, in the Royal College of Physicians, London, UK.    BOS is a leading European partnering event exclusively focused on...
  • Krakow, 31 August 2015 – Selvita will present at the upcoming BioPharm America™ 2015, which will be held at the Boston Mariott Copley Place in Boston, MA on September 15–17, 2015.   Pawel Przewiezlikowski, Selvita's Chief Executive Officer, will present at the conference as a part of the Cancer track. The presentation will take place...
  • Krakow, 14 August 2015 - Selvita will participate and exhibit at the upcoming Pharma ChemOutsourcing 2015 conference, which will take place 14 - 17 Septeber 2015, in Long Branch, NJ.   ChemOutsourcing is the largest USA-based API show attracting annually 700-800 chemists and business development personnel from the pharmaceutical, biotech,...
  •   Krakow, 06 August 2015 – Selvita, a global integrated drug discovery partner for the pharmaceutical and biotechnology industry, has been intensively expanding its operations. The total employment at Selvita increased to 261 people, including 86 PhDs in August.   The period of 2014-2015 marks a significant increase for Selvita in...
  • Krakow, 18 June 2015 - Selvita S.A. (WSE: SLV), the largest drug discovery company in Central and Eastern Europe will participate at ChemSpec 2015, which will be held in Cologne, Germany in June 24-25, 2015. The 30th Chemspec Europe exhibition and series of conferences will provide the visitors with a gateway to the international custom, fine...
  • Krakow, 10 June 2015 - Selvita S.A. (WSE: SLV), the largest drug discovery company in Central and Eastern Europe, will participate and present at the upcoming annual BIO International Convention, which will take place on June 15 -18, 2015, at the Pennsylvania Convention Center in Philadelphia, USA.   The presentation will be held by...
  • Krakow, 27 May 2015 – Selvita is a proud sponsor of the upcoming 16th Annual Drug Discovery Leaders’ Summit, which will take place 8 - 9 June in Berlin, Germany.   This summit brings together a host of senior level experts to discuss recent developments in the industry and debate the best strategies and solutions to improve drug...
  • Krakow, 12 May 2015 - Selvita, the largest drug discovery company in Central and Eastern Europe, generated a net profit of PLN 1.3 MM in the first quarter of 2015, which marks 119% increase as compared to Q1 2014. EBITDA reached value of PLN 1.9 MM, showing 80% y-o-y increase. Revenues amounted to PLN 12.0 MM, thus rising by 57% compared to...
  • Kraków, 06 May 2015 - Selvita will participate in the upcoming IATI Biomed 2015 Conference which is to be held May 12-14, 2015 in Tel-Aviv, Israel.    The IATI Biomed conference is a meeting place for healthcare’s industry players from Israel and abroad. Exuberance is felt everywhere; lectures, exhibition halls and partnership...
  • Kraków, 28 April 2015 - Selvita will exhibit at the upcoming PEGS - The Essential Protein Engineering Summit, which will take place in Boston, MA, 4-8 May 2015.   PEGS is the premier event for antibody and protein science research and the biologics industry, with more than 1,800 participants in attendance from over 30 countries. It's an...
  • April 24, 2015, Krakow, Poland - Selvita (WSE:SLV), the largest drug discovery company in Central and Eastern Europe, published the most recent data from its oncology programs at the AACR Annual Meeting 2015, which took place on 18 – 22 April 2015 in Philadelphia, PA, USA .   Data presented during this conference included recent results...
  • Kraków, 23 March 2015 - Selvita is pleased to announce, that Dr Krzysztof Brzozka, Selvita Chief Scientific Officer, will present at the upcoming 7th International Conference on Contemporary Oncology which will take place on 25-27 March 2015, in Poznan, Poland. Dr Brzozka will hold a presentation in the Heterogenity of Cancer and Therapeutic...
  • Kraków, 19 March 2015 - Selvita, the largest drug discovery company in Central and Eastern Europe, achieved its best ever revenues and first-ever full-year operating profit in 2014. Revenue amounted to PLN 41.3 MM, which is a 90% increase from 2013 revenue. Net profit was PLN 5.9 MM, compared to the loss of PLN 2.4 MM in 2013. EBITDA exceeded PLN...
  • Krakow, 25 February 2015 – Selvita will participate in and present at the upcoming BIO-Europe Spring which is the springtime counterpart to EBD Group’s flagship conference, BIO-Europe, and continues the tradition of providing life science companies with high caliber partnering opportunities.   The upcoming edition of the BIO-Europe...
  • Krakow, 20 February 2015 – Selvita will participate and exhibit at the 10th Annual Drug Discovery Chemistry conference, which will take place on 21-23 April 2015 in San Diego, CA.   Drug Discovery Chemistry is a dynamic conference for medicinal chemists working in pharma and biotech. Focused on discovery and optimization challenges of...
  • Krakow, 28 January 2015 - Selvita S.A. (WSE: SLV), the largest drug discovery company in Central and Eastern Europe, today announced that Pawel Przewiezlikowski, Chief Executive Officer of the company, will present at the upcoming 17th Annual BIO CEO & Investor Conference, which will take place on February 9 -10, at the Waldorf Astoria New...
  • Krakow, 16 December 2014 - Selvita, Poland-based integrated drug discovery partner for the pharmaceutical and biotechnology industry, has successfully completed its Initial Public Offering. Gross proceeds from the sale of 2,651,891 new shares amount to PLN 27.3 MM (US$ 8.1 MM), sold at the maximum announced price. Selvita plans to enter the main...
  • Krakow, 04 August 2014 - Selvita will participate and present at the BioPharm America™ 2014, which will be held at the Boston Mariott Copley Place in Boston, MA on September 22–24, 2014. Selvita's Chief Executive Officer will present at the conference as a part of the Cancer track. The presentation will take place on September 23, 2014, at...
  • Krakow, 09 June 2014 - Selvita, a Polish drug discovery company, listed on the NewConnect Market of the Warsaw Stock exchange and the National Centre for Research and Development concluded an agreement for the execution and financing of the KIND-P1 research program, comprising preclinical studies of Selvita's two most advanced oncology projects,...
  •   Krakow, 02 June 2014 - Selvita will participate in the 2014 edition of BIO International COnvention, taking place in San Diego, USA, on June 23-26 2014.   The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech. This conference which offers unprecedented...
  • Cambridge, MA and Krakow, Poland, 22 May 2014 — H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision oncology treatments, and Selvita (PL: SLV), one of the largest drug discovery companies in Eastern Europe, announced today that they have achieved the first research milestone in their...
  • Krakow, 16 May 2014 - Selvita will exhibit at ChemSpec 2014, which will be held in Budapest, Hungary in June 18-19, 2014. We cordially invite you to visit our booth no. A22. The 29th Chemspec Europe exhibition and series of conferences will provide the visitors with a gateway to the international custom, fine and speciality chemicals...
  •   Krakow, 13 May 2014 - Selvita, a drug discovery company listed on Warsaw Stock Exchange NewConnect market reported PLN0.57m net earnings in Q1 2014, compared to PLN1.0 m net loss in Q1 2013. This is the second quarter in a row that Selvita finished with a profit, after the company reached its first break-even in Q4 2013. Selvita's revenues...
  •   Krakow, 12 May 2014 - Selvita will participate the 15th Annual Drug Discovery Summit 2014 which will take place on 2-3 June 2014 in Geneva, Switzerland.   This summit brings together a host of senior level experts to discuss recent developments in the industry and debate the best strategies and solutions to improve drug discovery...
  • Krakow, 11th of April 2014 - Selvita will participate and exhibt in the 13th Central European Forum of Biotechnology and Innovative BioEconomy. The biggest and the most important international event for biotechnology in the region of Central Europe and will be held on 28th-29th of May in Lodz. Since the year 2000 the main goal of BioForum is to...
  • Krakow, 1st of April 2014 – Selvita will participate and present at Protein Kinases in Drug Discovery – Europe, which will be held in Berlin, Germany, on 8-9 May 2014. Presentation of Krzysztof Brzozka, Executive Vice President, Chief Scientific Officer of Selvita S.A., entitled "Targeting MNK1/2 Kinases as Promising Anticancer Targets...
  • Krakow, Poland, 11 March 2014 – Selvita, the largest independent drug discovery company in Central and Eastern Europe, will present new data at poster sessions at AACR Annual Meeting 2014, which will take place on April 5 - 9, 2014 at San Diego Convention Center, San Diego, California, USA. Selvita will present two posters: The poster...
  • The fourth quarter of 2013 is the first reporting period in which the Capital Group Selvita S.A. recorded an operating profit (excluding one-offs). The Group’s net profit for the fourth quarter amounted to PLN 335.2k (which translates into a net margin of 6.7%), while in the corresponding period of the previous year the Group recorded a net loss...
  • Krakow, 18th of February 2014 - Selvita Group received a GMP certificate. On February 11 2014, after positive inspection conducted by the Main Pharmaceutical Inspectorate (the competent authority of Poland granting GMP certificates), BioCentrum, a part of Selvita Group received a certificate of compliance with the principles of Good Manufacturing...
  • Krakow, 13th of February 2014 - BIO-Europe Spring® is the springtime counterpart to EBD Group’s flagship conference, BIO-Europe®, and continues the tradition of providing life science companies with high caliber partnering opportunities. Featuring EBD Group’s sophisticated, web-based partnering system, partneringONE®, the event enables...
  • Krakow, 11th of February 2014 - The 7th Annual European Life Sciences CEO Forum for Partnering & Investing is being held on 4th-5th March 2014 at the Hilton Zurich Airport Hotel, Switzerland. This event is recognized as a leading international stage for those interested in investing in the Life Science and Biotech industries and is highly...
  • Krakow, 10th of January 2014 - Selvita, Poland-based integrated drug discovery partner for the pharmaceutical and biotechnology industry, has extended its chemistry research collaboration with Chiesi Farmaceutici from Italy. “We are very proud to be working for such renowned and innovative company as Chiesi. Chiesi projects always involve...